Is Recursion Pharmaceuticals Overvalued After 57.9% Decline?
Recursion Pharmaceuticals (RXRX) has experienced a 57.9% stock decline over the past year, raising valuation concerns. What does this mean for investors?
Yahoo Finance · 3 min read
RXRX Recursion Pharmaceuticals
Healthcare
AI Drug Discovery
Latest news and analysis for Recursion Pharmaceuticals (RXRX).
Current Price
$3.67
-0.10
(-2.65%)
Market data may be delayed
Price Chart
Loading chart...
All Articles for RXRX
Yahoo Finance · 3 min read